Stem Cell Factor-responsive FcepsilonRI Bearing Human Mast Cell Line LAD2


A human mast cell line LAD2 that more closely resembles normal in vivo and in vitro human mast cells by expressing functional FcepsilonRI receptors and responding to stem cell factor (SCF) with proliferation, as described in Leuk Res. 2003 Aug;27(8):677-82 and developed by the laboratory of Dr. Dean Metcalfe at the National Institute of Allergy and Infectious Diseases.  This cell line also releases mediators by cross-linking FcgammaRI (CD64) receptors and express FcgammaRII (CD32).

Potential Commercial Applications: Competitive Advantages:
  • A research material that can be used in the development of assays, validation of products or in quality control.
 
  • Speed up product development with NIH developed material that has already been tested and validated.


Inventors:

Arnold Kirshenbaum (NIAID)  ➽ more inventions...

Cem Akin (NIAID)  ➽ more inventions...

Dean Metcalfe (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. PCT/US03/02790
Research Material - Patent protection is no longer being pursued for this technology. (IC Reference No. 2001-022)

Publications:
Kirshenbaum AS, et al. PMID 12801524

Licensing Contact:
Dianca Finch, Ph.D.
Email: dianca.finch@nih.gov
Phone: 240-669-5503

OTT Reference No: E-279-2001/0
Updated: Nov 6, 2017